Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.

Item

http://www.wikidata.org/entity/Q36597063

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.

@ast

Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.

@en

type

Item

label

Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.

@ast

Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.

@en

prefLabel

Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.

@ast

Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.

@en

P1476

Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.

@en

P2093

Philip E Shaheen

http://www.w3.org/2001/XMLSchema#string

Ronald M Bukowski

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

The biology of VEGF and its receptors

A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Epidermal growth factor-related peptides and their receptors in human malignancies

Cancer statistics, 2005

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

P304

640-656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07357900600896315

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16982470

http://www.w3.org/2001/XMLSchema#string